September 25, 2024 06:57 GMT
HEALTHCARE: Roche (ROSW: Aa2/AA): Announces More Targeted Pipeline
HEALTHCARE
- WSJ interview yesterday
- Company is cutting 25% of its pipeline following Alzheimer's and lung cancer fails
- Focus will be on obesity and ophthalmology
- Vabysmo selling c.CHF4bn per year was launched in 2022 but few other success stories
- R&D spend was CHF 13.4bn last year: 23% of revenue
- Second highest in the industry behind Merck who are trying to replace Keytruda
- Investor Day 30th Sep will provide more details
66 words